• Latest

Medihauxe Pharma sets up the state of the art Life saving medicine facility at Cochin at a cost of Rs 10crore

It also plans to expand to other states as well   Cochin, October 04, 2021:The Hyderabad based 24 years old leading…

• Approval

Lupin and Mylan Receive European Marketing Authorization for Nepexto®, Biosimilar Etanercept

Mumbai, June 04, 2020: Lupin Limited (Lupin) and Mylan N.V. (NASDAQ: MYL) today announced that the European Commission (EC) has…

• Market

EISAI INDIA AND MYLAN ENTER INTO CO-EXCLUSIVE MARKETING AGREEMENTTO COMMERCILIZE TECERIS® THE SECOND ERIBULIN BRAND IN INDIA

TECERIS® aimed at expanding access to metastatic breast cancer patients in India Vishakhapatnam, September 29, 2019: Eisai Pharmaceuticals India Pvt.…

• Market

Eisai’s Promotion and Distribution Agreement with Mylan India for Eribulin Second Brand in India

Aiming to Expand Availability of Eribulin to Patients in India with Two Brands Halaven and Teceris Tokyo, September 21, 2019: …

• Archives

Mylan announces the 2018 Mylan Hackathon to ‘Connect, Collaborate and Innovate’

Mylan, November 18, 2018: a global pharmaceutical company is hosting the 2018 Mylan Hackathon at its Global Center in Bengaluru on October 13-14,…

U.S. FDA Approves Mylan and Biocon’s Fulphila™ (pegfilgrastim-jmdb), the First Biosimilar to Neulasta®

Fulphila is expected to be the first biosimilar pegfilgrastim available in the U.S. to help patients with nonmyeloid cancers reduce…

• Featured

Why 2018 will be a challenging year for pharmaceuticals

New Delhi, March 29, 2018: Management teams were generally optimistic on the outlook for domestic Indian markets, with sales growth…

• Extras

Mylan launches Saugella® in India, a ‘natural’ feminine intimate hygiene product, backed by 40 years of research

SAUGELLA®, with natural plant extracts, is the preferred brand for intimate hygiene among customers in over 30 countries and is the only…